FJV

4-(8-(piperazin-1-yl)-1,2,3,4-tetrahydro-[1,2,3]triazino[4',5':4,5]thieno[2,3-c]isoquinolin-5-yl)morpholine

Created:	2018-04-05
Last modified:	2021-03-13

Find Related PDB Entry
1 entries where FJV is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	54
Chiral Atom Count	0
Bond Count	59
Aromatic Bond Count	15

2D diagram of FJV

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	4-(8-(piperazin-1-yl)-1,2,3,4-tetrahydro-[1,2,3]triazino[4',5':4,5]thieno[2,3-c]isoquinolin-5-yl)morpholine
Synonyms	5-(morpholin-4-yl)-8-(piperazin-1-yl)-1,2,3,4-tetrahydro[1,2,3]triazino[4',5':4,5]thieno[2,3-c]isoquinoline
Systematic Name (OpenEye OEToolkits)	4-(13-piperazin-1-yl-11-thia-9,14,15,16-tetrazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca-1(10),2(7),8,12(17),13,15-hexaen-8-yl)morpholine
Formula	C₂₀ H₂₅ N₇ O S
Molecular Weight	411.524
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	C1COCCN1c3c2CCCCc2c4c(n3)sc5c4nnnc5N6CCNCC6
SMILES	CACTVS	3.385	C1CCc2c(C1)c(nc3sc4c(nnnc4c23)N5CCNCC5)N6CCOCC6
SMILES	OpenEye OEToolkits	2.0.6	C1CCc2c(c3c4c(c(nnn4)N5CCNCC5)sc3nc2N6CCOCC6)C1
Canonical SMILES	CACTVS	3.385	C1CCc2c(C1)c(nc3sc4c(nnnc4c23)N5CCNCC5)N6CCOCC6
Canonical SMILES	OpenEye OEToolkits	2.0.6	C1CCc2c(c3c4c(c(nnn4)N5CCNCC5)sc3nc2N6CCOCC6)C1
InChI	InChI	1.03	InChI=1S/C20H25N7OS/c1-2-4-14-13(3-1)15-16-17(19(24-25-23-16)26-7-5-21-6-8-26)29-20(15)22-18(14)27-9-11-28-12-10-27/h21H,1-12H2
InChIKey	InChI	1.03	ZPVQONCMKZBGTB-UHFFFAOYSA-N

Related Resource References

Resource Name	Reference
Pharos	CHEMBL3980115
PubChem	1071983
ChEMBL	CHEMBL3980115

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.